Portal de Periódicos da CAPES

Hereditary hypo/de‐pigmented dermatoses: An overview

2008; Wiley; Volume: 47; Issue: 10 Linguagem: Inglês

10.1111/j.1365-4632.2008.03105.x

1365-4632

Virendra Sehgal, Govind Srivastava,

Genetic and rare skin diseases.

International Journal of DermatologyVolume 47, Issue 10 p. 1041-1050 Hereditary hypo/de-pigmented dermatoses: An overview Virendra N. Sehgal MD, FNASc, FAMS, FRAS (Lond.), Virendra N. Sehgal MD, FNASc, FAMS, FRAS (Lond.) From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, Skin Institute and Research Society, New Delhi, IndiaSearch for more papers by this authorGovind Srivastava MD, MNAMS, Govind Srivastava MD, MNAMS From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, Skin Institute and Research Society, New Delhi, IndiaSearch for more papers by this author Virendra N. Sehgal MD, FNASc, FAMS, FRAS (Lond.), Virendra N. Sehgal MD, FNASc, FAMS, FRAS (Lond.) From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, Skin Institute and Research Society, New Delhi, IndiaSearch for more papers by this authorGovind Srivastava MD, MNAMS, Govind Srivastava MD, MNAMS From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, Skin Institute and Research Society, New Delhi, IndiaSearch for more papers by this author First published: 24 September 2008 https://doi.org/10.1111/j.1365-4632.2008.03105.xCitations: 9 Prof. Virendra N. Sehgal A/6, Panchwati Delhi – 110 033 India E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Spritz RA, Hearing VJ Jr. Genetic disorders of pigmentation. Adv Hum Genet 1994; 22: 1– 45. 2 Witkop CJ. Dipigmentation of the general and oral tissues and their genetic foundations. Ala J Med Sci 1979; 16: 330– 343. 3 Avila NA, Brantly M, Premkumar A, Huizing M, Dwyer A, Gahl WA. Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol 2002; 179: 887– 892. 4 Anikster Y, Huizing M, White J, et al. Mutation of a new gene caused a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. Nat Genet 2001; 28: 376– 380. 5 Bolognia JL, Pawelak NM. Biology of hypopigmentation. J Am Acad Dermatol 1988; 19: 217– 255. 6 Witkop CJ, Quevedo WC, Fitzpatrick TB, et al. Albinism. In: CR Scriver, ed. The Metabolic Basis of Inherited Diseases, 6th Ed. New York: Mc Graw Hill, 1989: 105– 111. 7 Tomita Y. Tyrosinase gene mutations causing oculocutaneous albinisms. J Invest Dermatol 1993; 100: 1865– 1905. 8 Passeron T, Mantoux F, Ortonne JP. Genetic disorders of pigmentation. Clin Dermatol 2005; 23: 56– 67. 9 Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristic of patients with a form of oculocutaneous albimism (Hermansky-Pudlak syndrome). N Engl J Med 1998; 338: 1258– 1264. 10 Shanahan F, Randolph L, King R, et al. Hermansky-Pudlak syndrome – an immunologic assessment of 15 cases. Am J Med 1988; 85: 823– 828. 11 Schachne JP, Glaser N, Lee SH, et al. Hermansky-Pudlak syndrome – case report and clinicopathological review. J Am Acad Dermatol 1990; 22: 926– 932. 12 King RA, Witkop CJ Jr. Hair bulb tyrosinase activity in oculocutaneous albinism. Nature 1976; 263: 69– 71. 13 Okoro AN. Albinism in Nigeria. A clinical and social study. Br J Dermatol 1975; 92: 485– 492. 14 Taylor WO. Hereditary puzzle in albinisum. Heterogeneity or phenotypical variation? Trans Opthalmol Soc UK 1983; 103: 318– 330. 15 Kromberg JG, Jenkins T. Albinism in South African Negro III. Genetic counselling issue. J Blosoc Sci 1984; 16: 99– 108. 16 Dube P, Der Kaloustian VM, Demczuk S, et al. A new association of congenital hydrocephalus, albinism, megalocornea, and retinal coloboma in a syndromic child. A clinical and genetic study. Ophthalmic Genet 2000; 21: 211– 216. 17 Inagaki K, Suzuki T, Shimizu H, et al. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet 2004; 74: 466– 471. 18 Ramsay M, Colman MA, Stevens G, et al. The tyrosinase positive oculocutaneous albinism locus maps to chromosome 15Q112-Q12. Am J Hum Genet 1992; 51: 879– 884. 19 Hu F, Hanifin JM, Prescott GH, et al. Yellow mutant albinism-cytochemical, ultra-structural and genetic characterization suggesting multiple allelism. Am J Hum Genet 1980; 32: 387– 395. 20 Shiloh Y, Litvak G, Ziv Y, et al. Genetic mapping of X-linked albinism–deafness syndrome. (ADFN) to Xq26.3-q27.I. Am J Hum Genet 1990; 47: 20– 27. 21 Charles SJ, Green JS, Moore AT, et al. Genetic mapping of X-linked ocular albinism-linkage analysis in a large Newfoundland kindred. Genomic 1993; 16: 259– 261. 22 Rebbeck TR, Jordan HA, Schnur RE, et al. Utility of linked markers in genetic counseling: estimation of carrier risks in X-linked ocular albinism. Am J Med Genet 1997; 70: 58– 66. 23 Boissy RE, Nordlund JJ. Molecular basis of congenital hypopigmentary disorders in humans: A review. Pigment Cell Res 1997; 10: 12– 24. 24 Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphism of pigmentation gene associated with albinism. Hum Mutal 1999; 13: 99– 115. 25 Incerti B, Cortese K, Pizzigoni A, et al. OA1 knock-out-new insights on the pathogenesis of ocular albinism type I. Hum Mol Genet 2000; 9: 2781– 2788. 26 Newton JM, Cohen-Barak O, Hagiwara N, et al. Mutations in the human orthologue of the mouse under-white gene underlie a new form of oculocutaneous albinism OCA4. Am J Hum Genet 2001; 69: 981– 988. 27 Toyofuku K, Valencia JC, Kushimoto T, et al. The etiology of oculocutaneous albinism (OCA) type II. The pink protein modulates the processing and transport of tyrosinase. Pigment Cell Res 2002; 15: 217– 224. 28 Bergsma DR, Kaiser Kupfer M. A new form of albinism. Am J Opthalmol 1974; 77: 837– 844. 29 Busti Rosner L. Two cases of incomplete universal albinism (albinoidism) of a peculiar biotype in a Valais family. J Genet Hum 1956; 5: 197– 215. 30 Fulton AB. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak Syndrome) [correction of (Hennansky-Pudlak)]. Arch Opthol 1999; 117: 251– 252. 31 Sagai T, Koide T, Endo M, et al. Rim-2 (recombination induced mutation-2) is a new allele of pearl and a mouse model of human Hermansky-Pudlak syndrome (HPS): genetic and physical mapping. Mamm Genome 1998; 9: 2– 7. 32 Witkop CJ, Krumwiede M, Sedano H, et al. Reliability of absent platelet dense bodies as a diagnostic criteria for Hermansky-Pudlak Syndrome. Am J Haematol 1987; 26: 305– 311. 33 Martina JA, Moriyama K, Bonifacino JS. BLOC-3 a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. J Biol Chem 2003; 278: 29376– 29384. 34 Dell'Angelica EC, Sholeler-Suk V, Aguilar RC, et al. Altered trafficking of lysosomal protein in Hermansky-Pudlak Syndrome due to mutations in the beta 3A sub unit of the AP-3 adapter. Mol Cell 1999; 3: 11– 21. 35 Sugita M, Cao X, Watts GF, et al. Failure of trafficking and antigen presentation by CD-1 in AP-3 deficient cells. Immunity 2002; 16: 697– 706. 36 Suzuki T, Li W, Zhang Q, et al. The gene mutated in Cocoa mice, carrying a defect in organelle bio-genesis is a homologue of the human Hermansky-Pudlak Syndrome-3 gene. Genomics 2001; 78: 30– 37. 37 Zhang Q, Zhao B, Li W, et al. Ru-2 and Ru encode mouse orthologs of the gene mutated in human Hermansky–Pudlak Syndrome types 5 and 6. Nato Genet 2003; 33: 145– 153. 38 Li W, Zhang Q, Oiso N, et al. Hermansky-Pudlak Syndrome type 7 results from the mutant dysbinding member of the biogenesis of lysosome-related organdle complex 1 (BLOC-1). Nat Genet 2003; 35: 84– 89. 39 Tchernev VT, Mansfield TA, Giot L, et al. The Chediak-Hermansky protein interacts with SNARE complex and signal transduction proteins. Mol Med 2002; 8: 56– 64. 40 Faigle W, Raposo G, Tenza D, et al. Deficient peptide loading and MHC class II endosomal sorting in human state- The Chediak Higashi syndrome. J Cell Biol 1998; 141: 1121– 1134. 41 Lutzner MA, Lowrie CT, Jorden HW. Giant granules in leukocytes of the beige mouse. J Hered 1967; 58: 299– 300. 42 Windhorst DB, Zelickson AS, Good RA. A human pigmentary dilution based on a heritable subcellular structured defect. J Invest Dermatol 1968; 50: 9– 18. 43 Padgett GA, Reiquam CW, Gorham JR, et al. Comparative studies of the Chediak Higashi Syndrome. Am J Pathol 1967; 51: 553– 571. 44 Choi JH, Hoon SK, Lee KH, et al. Three cases of Waardenburg Syndrome type ×2 in a Korean family. Korean J Opthalmol 2004; 18: 185– 189. 45 Denli YG, Yucel A, Gunasti S, et al. A family with Waardenburg syndrome. J Dermatol 2004; 31: 434– 436. 46 Nayak CS, Isaacson G. World-wide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 2003; 112: 7– 20. 47 Waardenburg PJ. A new syndrome combining developmental anomalies of the eyelid, eyebrows and nose root with pigmentary defects of the iris, head hair with congenital deafness. Am J Human Genet 1951; 3: 195– 253. 48 Fisch T. Deafness as a part of an hereditary syndrome. J Laryngol Otol 1959; 73: 355– 382. 49 Di George AM, Olmsted RW, Harley RD. Waardenburg's syndrome. A syndrome of heterochromia of the irides, lateral displacement of the medial canthi and lacrimal puncta, congenital deafness, and other characteristic associated defects. Journal of Pediatrics 1960; 57: 649– 669. 50 Partington MW. Waardenburg's syndrome and heterochromia iridum in a school population. Cam Med Assoc 1964; 90: 1008– 1017. 51 Ortonne JP. Piebaldism, Waardenburg's syndrome and related disorders "Neural crest depigmentation syndromes". Dermatol Clin 1988; 6: 205– 216. 52 Toki F, Suzuki N, Inoue K, et al. Intestinal aganglinosis associated with the Waardenburg's syndrome: report of two cases and review of the literature. Pediatr Surg Int 2003; 19: 725– 728. 53 Cant JS, Martin AJ. Waardenburg's syndrome. Report of a family. Br J Opthlomol 1967; 51: 755– 759. 54 Madden C, Halsted MJ, Hopken RJ, et al. Temporal bone abnormalities associated with hearing loss in Waardenburg syndrome. Laryngoscope 2003; 113: 2035– 2041. 55 Partsch CJ. [Hereditary deafness in Waardenburg-Klein syndrome]. Z Laryngol Rhinol Otol 1962 Nov; 41: 752– 762. 56 Reed WB, Stone VM, Boder E, et al. Pigmentary disorders in association with congenital deafness. Arch Dermatol 1967; 95: 176– 186. 57 Kaplan P, De Chaderevian JP. Piebaldism – Waardenburg syndrome: Histopathologic evidence for a neural crest syndrome. Am J Med Genet 1988; 31: 679– 688. 58 Liu XZ, Newton VE, Read AP. Waardenburg syndrome type II-phenotype findings and diagnostic criteria. Am J Med Genet 1995; 55: 95– 100. 59 Perrot H, Ortonne JP, Thivolet J. Ultrastructural study of leukodermic skin in Waardenburg-Klein syndrome. Acta Derm Verereol (Stock) 1977; 57: 195– 200. 60 Shah KN, Dalal SJ, Desai MP, et al. White forelock, pigmentary disorder of irides, and long segment Hirschsprung disease: possible variant of Waardenburg's syndrome. J Pediatr 1981; 99: 432– 435. 61 Mosher DB, Fitzpatrick TB. Piebaldism. Arch Dermatol 1988; 124: 364– 365. 62 Spritz RA. Piebaldism, Waardernburgs syndrome and related disorders of melanocyte development. Semin Cutan Med Surg 1997; 16: 15– 23. 63 Comings DE, Odland GF. Partial albinism. JAMA 1966; 195: 519– 523. 64 Cooke JV. Familial white skin spotting (piebaldism) ("partial albinism") with white forelock. J Pediatr 1952; 41: 1– 12. 65 Jimbow K, Fitzpatrick TB, Szabo G, et al. Congenital circumscribed hypomelanosis: a characterization based on electron microscopic study of tuberous sclerosis, nevus depigmentosus, and piebaldism. J Invest Dermatol 1975; 64: 50– 56. 66 Breathnach AS, Fitzpatrick TB, Wyllie LM. Electron microcopy of melanocytes in human piebaldism. J Invest Dermatol 1965; 45: 28– 37. 67 Hayashibe K, Mishima Y. Tyrosinase positive melanocyte distribution and induction of pigmentation in human piebald skin. Arch Dermatol 1988; 124: 381– 386. 68 Ward KA, Moss C, Sanders DS. Human piebaldism – relationship between phenotype and site of kit gene mutation. Br J Dermatol 1995; 132: 929– 935. 69 Ezoe K, Holmes SA, Ho L, et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet 1995; 56: 58– 66. 70 Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor) proto-oncogene in human piebaldism. Proc Natl Acad Sci USA 1991; 88: 8696– 8699. 71 Griscelli C, Durandy A, Guy-grand D, et al. A syndrome associating partial albinism and immunodeficiency. Am J Med 1968; 65: 691– 702. 72 Rogers SL, Karcher RL, Roland JT, et al. Regulation of melanosomes movement in the cell cycle by reversible association with Myosin V. J Cell Biol 1999; 146: 1265– 1276. 73 Bahadoran P, Aberdam E, Mantoux F, et al. Rab 27-a: A key to melanosome transport in human melanocytes. J Cell Biol 2001; 152: 843– 850. 74 Menasche G, Ho CH, Sanal O, et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A-F exom deletion (GS1). J Clin Invest 2003; 112: 450– 456. 75 Glover MT, Brett EM, Atherton DJ. Hypomelanosis of Ito-spectrum of the disease. J Pediatr 1989; 115: 75– 80. 76 Flannery DB. Pigmentary dysplasias, hypomelanosis of Ito and genetic Mosaicism. Am J Med Genet 1990; 35: 18– 21. 77 Moss C, Burn J. Genetic counselling in hypomelanosis of Ito: Case report and Review. Clin Genet 1988; 34: 109– 115. 78 Ruiz-Maldonado R, Toussaint S, Tamayo L, et al. Hypomelanosis of Ito – diagnostic criteria and report of 41 cases. Pediatr Dermatol 1992; 9: 1– 10. 79 Ritter CL, Steele MW, Wenger SL. Chromosome mosaicism in hypomelonosis of Ito. Am J Med Genet 1990; 35: 18– 21. 80 Hatchwell E. Hypomelanosis of Ito and X–autosome translocations – a unifying hypothesis. J Med Genet 1996; 33: 177– 183. 81 Duran-McKinster C, Moises C, Rodriguez-Jurado R, et al. Streptococcal exanthem in Blaschko-linear pattern – clinical evidence for genetic mosaicism in hypomelanosis of Ito. Pediatr Dermatol 2002; 19: 423– 425. 82 Kuster W, Konig A. Hypomelanosis of Ito – no entity but a cutaneous sign of Mosaicism. Am J Med Genet 1999; 85: 346– 350. 83 Nehal KS, PeBenito R, Orlow SJ. Analysis of 54 cases of hypopigmentation and hyperpigmentation along the lines of Blaschko. Arch Dermatol 1996; 132: 1167– 1170. 84 Bolognia JL, Orlow SJ, Glick SA. Lines of Blaschko. J Am Acad Dermatol 1994; 31: 157– 190. 85 Ruggieri M. Familial hypomelanosis of Ito – implications for genetic counseling. Am J Med Genet 2000; 95: 82– 84. 86 Steijlen PM, Vietor HE, Steensel MV, et al. Sweat testing in hypomelanosis of Ito divergent results reflecting genetic heterogeneity. Eur J Dermatol 2000; 10: 217– 219. 87 Gutman I, Dunn D, Behrens M, et al. Hypopigmented iris spot – an early sign of tuberous sclerosis. Ophthalmology 1982; 89: 1155– 1159. 88 Awan KJ. Leaf-shaped lesions of the ocular fundus and white eyelashes in tuberous sclerosis. South Med J 1982; 75: 227– 228. 89 Winship IM, Connor JM, Beighton PH. Genetic heterogeneity in tuberous sclerosis – phenotypic correlation. J Med Genet 1990; 27: 418– 421. 90 Hurwitz S, Braverman IM. White spots in tuberous sclerosis. J Pediatr 1970; 77: 587– 594. 91 Fitzpatrick TB, Szabo G, Hori Y, et al. White leaf-shaped macules. Earliest visible sign of tuberous sclerosis. Arch Dermatol 1968; 98: 1– 6. 92 Sampson JR, Harris PC. The molecular genetics of tuberous sclerosis. Hum Mol Genet 1994; 3: Spec No: 1477– 1480. 93 Van Slegtenhorst M, De Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC-1 and chromosome 9q34. Science 1997; 227: 805– 808. 94 Benvenuto G, Li S, Brown SJ, et al. The tuberous sclerosis -1 (TSC-1) gene product hamartin suppresses cell growth product tuberin by inhibiting its ubiquitinations. Oncogene 2000; 19: 6306– 6316. 95 Hyman MH, Whittemore VH. National Institute of Health consensus conference: Tuberous sclerosis complex. Arch Neurol 2000; 57: 662– 665. 96 Zvulunov A, Esterly NB. Neurocutaneous syndrome associated with pigmentary skin lesions. J Am Acad Dermatol 1995; 32: 915– 935. 97 Di Lermia V. Segmental nerves depigmentosus – analysis of 20 patients. Pediatr Dermatol 1999; 16: 349– 353. 98 Fukai K, Ishil M, Kadoya A, et al. Nevus depigmentosus systematicus with partial yellow scalp hair due to selective suppression of eumelanogenesis. Pediatr Dermatol 1993; 10: 205– 208. 99 Kirkilionis AJ, Chudley AE, Gregory CA, et al. Molecular and clinical overlap of Angelman and Prader–Willi Syndrome phenotypes. Am J Med Genet 1991; 40: 454. 100 Tietz W. A syndrome of deaf-mutism associated with albinism showing dominant autosomal inheritance. Am J Hum Genet 1963; 15: 259– 264. 101 Ziprkowski L, Krakowski A, Adam A, et al. Partial albinism and deaf-mutism due to a recessive sex-linked gene. Arch Dermatol 1962; 86: 530– 539. 102 Cross He, McKusick VA, Breen W. A new oculocerebral syndrome with hypopigmetation. J Pediater 1976; 70: 398– 406. 103 Sehgal VN, Srivastava G. Vitiligo: Auto-immunity and immune responses. Int J Dermatol 2006; 45: 583– 590. 104 Spritz RA, Gowan K, Bennett DC, et al. Novel vitiligo susceptibility loci chromosome -7 (A1S2) and -8 (A1S3), confirmation of SLEV-1 on chromosome-17, and their role in an autoimmune diathesis. Am J Hum Genet 2004; 74: 188– 191. 105 Fain PR, Gowan K, LaBerge GS, et al. A genome wide screen for generalized vitiligo confirmation of A1S1 on chromosome Ip31 and evidence for additional susceptibility loci. Am J Hum Genet 2003; 72: 1560– 1564. 106 Alkhateeb A, Stekler GL, Old W, et al. Mapping of an autoimmunity susceptibility locus (A1S1) to chromosome 1p31.3-p32.2. Hum Mol Genet 2002; 11: 661– 667. 107 Kopf AW, Morrill SD, Silberberg I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965; 92: 14– 35. 108 Ortonne JP. Halo nevus. In: JP Ortonne, DB Mosher, TB Fitzpatrick, eds. Vitiligo and other hypomelonosis of hair and skin, 1st edn. New York, NY: Plenum Medical, 1983: 567– 582. 109 Wayte DM, Helwig EB. Helo nevi. Cancer 1968; 22: 69– 70. 110 Copeman PW, Lewis MG, Phillips TM, et al. Immunological associations of the halo naevus with cutaneous malignant melanoma. Br J Dermatol 1973; 88: 127– 137. 111 Gauthier Y, Surleve-Bazeille JE, Gauther O. Ultrastructure of halo nevis. J Cutan Pathol 1975; 2: 71– 81. 112 Swanson JL, Wayte DM, Helwig EB. Ultrastructure of halo nevi. J Invest Dermatol 1968; 50: 434– 437. 113 Fleisher TL, Zeligman I. Cutanoeus findings in phenylketonuria. Arch Dermatol 1960; 81: 818– 902. 114 Woolf LI. Phenylketonuria and its variant. West J Med 1979; 131: 324– 328. 115 Kaufman S. Differential diagnosis of variant forms of hyperphenylalanemia. Pediatrics 1980; 65: 840– 844. 116 Brenton DP, Cusworth DC, Biddle SA, et al. Pregnancy and homocystinuria. Ann Clin Biochem 1977; 14: 161– 164. 117 Grieco AJ. Homo-cystinuria – pathogenetic mechanism. Am J Med Sci 1977; 273: 120– 124. 118 Woody NC, Synder CH, Harris JA. Histidinemia. Am J Dis Child 1965; 110: 606– 608. 119 Danks DM, Campbell PE, Walker-Smith J, et al. Menke's kinky hair syndrome. Lancet 1972; 1: 1100– 1101. Citing Literature Volume47, Issue10October 2008Pages 1041-1050 ReferencesRelatedInformation